Being marked as an “other” outside of the circle of human concern expresses tension between principles of liberty and equality and exacerbates health inequity.
AMA J Ethics. 2021;23(2):E166-174. doi:
10.1001/amajethics.2021.166.
Tina K. Sacks, PhD, Katie Savin, MSW, and Quenette L. Walton, PhD, LCSW
Would you question health decisions made by a 37-year old Black woman whose great-grandfather died in the US Public Health Service Syphilis Study at Tuskegee?
AMA J Ethics. 2021;23(2):E183-188. doi:
10.1001/amajethics.2021.183.
The opioid crisis, maternal death, and COVID-19 underscore trust as foundational to public health and call for redefinition of what it means to be a US clinician.
AMA J Ethics. 2021;23(3):E265-270. doi:
10.1001/amajethics.2021.265.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
COVID-19 underscores historical precedent for fear-driven responses that disregard autonomy among persons with low income who are also persons of color.
AMA J Ethics. 2021;23(11):E840-846. doi:
10.1001/amajethics.2021.840.